SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001607062-18-000366
Filing Date
2018-10-29
Accepted
2018-10-29 10:25:59
Documents
52
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q zander093018form10q.htm 10-Q 423856
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 8510
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 8395
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6232
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 6407
  Complete submission text file 0001607062-18-000366.txt   2251259

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE zander-20180930.xml EX-101.INS 313754
7 XBRL SCHEMA FILE zander-20180930.xsd EX-101.SCH 31825
8 XBRL CALCULATION FILE zander-20180930_cal.xml EX-101.CAL 31123
9 XBRL DEFINITION FILE zander-20180930_def.xml EX-101.DEF 134546
10 XBRL LABEL FILE zander-20180930_lab.xml EX-101.LAB 137525
11 XBRL PRESENTATION FILE zander-20180930_pre.xml EX-101.PRE 163483
Mailing Address 4700 SPRING ST LA MESA CA 91942-0274
Business Address 4700 SPRING ST LA MESA CA 91942-0274 6192279192
Zander Therapeutics, Inc (Filer) CIK: 0001718644 (see all company filings)

IRS No.: 474321638 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 333-220790 | Film No.: 181143076
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences